EAT
0.02
900%
XST
0.03
-40%
PIL
0.006
200%
HYD
0.014
-39.1%
TRI
0.031
158.3%
ENT
0.006
-33.3%
AGD
0.115
144.7%
ELS
1.345
-32.8%
CUF
0.04
135.3%
EOS
5.39
-29.9%
HWK
0.035
105.9%
EQS
0.012
-29.4%
AYM
0.006
100%
ERD
1.7
-29.2%
SKN
0.006
100%
T3D
0.085
-29.2%
NVA
1.535
98.1%
DTM
0.005
-28.6%
RML
0.086
91.1%
SPQ
0.01
-28.6%
CNJ
0.013
85.7%
1MC
0.05
-26.5%
RDN
0.009
80%
ATC
0.04
-25.9%
EUR
0.465
78.8%
DTR
0.4
-25.2%
RAU
0.31
72.2%
MTB
0.012
-25%
BIT
0.005
66.7%
RNX
0.006
-25%
RLC
0.005
66.7%
TEG
0.003
-25%
AON
0.013
62.5%
CDR
0.022
-24.1%
AMX
0.3
53.8%
DRO
4.59
-23.9%
BMG
0.023
53.3%
SLM
0.061
-23.8%
CAE
0.064
52.4%
PSL
0.032
-23.8%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759